Go Deep
Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 13,134 | 48.8 | 6.42 | 0.08 | 1,911.30 |
| Oct 2026 | 22,187 | 48.8 | 3.28 | 0.08 | 976.35 |
Remus Pharmaceuticals Limited Quarterly Results
| Line Item | Mar 2026 | Mar 2025 |
|---|---|---|
| Revenue | 4,534,300,000.0 | 3,477,500,000.0 |
| Net Profit | 194,900,000.0 | 160,100,000.0 |
| EPS | 20.9 | 17.5 |
Remus Pharmaceuticals Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2022 |
|---|---|---|---|---|
| Revenue | 8,385,900,000.0 | 6,103,200,000.0 | 2,103,100,000.0 | 247,171,000.0 |
| Net Profit | 369,900,000.0 | 290,700,000.0 | 205,200,000.0 | 33,857,000.0 |
| EPS | — | 16.3 | 21.5 | 2.9 |
Remus Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 5,786,500,000.0 | 4,326,400,000.0 | 3,331,100,000.0 | 349,300,000.0 | — |
| Total Liabilities | 1,909,200,000.0 | 1,500,900,000.0 | 1,579,000,000.0 | 158,500,000.0 | — |
| Total Equity | 3,509,900,000.0 | 2,558,600,000.0 | 1,576,900,000.0 | 190,800,000.0 | — |
Owes vs Owns
Remus Pharmaceuticals Limited owed ₹0.33 for every ₹1 it owned in Mar 2026, down from ₹0.45 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.33× | 0.35× | 0.47× | 0.45× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Remus Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 9.5%Receivables 24.2%Inventory 12.5%Fixed assets (tangible) 3.1%Intangible assets 1.6%Long-term investments 44.4%Other assets 4.8%
How it's funded — Mar 2026
Short-term debt 3.0%Long-term debt 1.0%Payables 13.1%Other liabilities 15.9%Shareholders' equity 67.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 54.9 | 27.3 | 25.0 | 3.0 |
| Receivables | 139.8 | 108.0 | 115.3 | 4.7 |
| Inventory | 72.1 | 51.6 | 43.1 | 0.4 |
| Fixed assets (tangible) | 17.9 | 6.8 | 4.9 | 2.9 |
| Intangible assets | 9.0 | 8.7 | 8.9 | 0.1 |
| Long-term investments | 257.0 | 195.3 | 20.5 | 20.6 |
| Other assets | 28.0 | 34.9 | 115.4 | 3.3 |
| Liabilities & equity | ||||
| Short-term debt | 17.4 | 17.5 | 8.6 | 0.9 |
| Long-term debt | 5.7 | 3.3 | 3.0 | 7.1 |
| Payables | 76.0 | 71.3 | 93.7 | 3.5 |
| Other liabilities | 91.8 | 58.0 | 52.6 | 4.4 |
| Shareholders' equity | 387.7 | 282.6 | 175.2 | 19.1 |
| Net tangible assets | 342.0 | 247.1 | 148.8 | 19.0 |
Remus Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2022 |
|---|---|---|---|---|
| Operating Activities | 181,600,000.0 | 69,800,000.0 | 13,500,000.0 | 50,378,000.0 |
| Investing Activities | -150,300,000.0 | -105,500,000.0 | -301,100,000.0 | -45,454,000.0 |
| Financing Activities | 14,700,000.0 | 60,700,000.0 | 276,700,000.0 | -1,744,000.0 |